DBV Technologies: Information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2025

DBV Technologies: Information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2025

May 06, 2025 | Last Trade: US$10.83 0.16 -1.46

Information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2025

(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)

Market : NYSE Euronext Paris
ISIN Code: FR 0010417345

Date	Total number of shares	Total number of voting rights
04/30/2025	136,948,872	Total gross of voting rights: 136,948,872
04/30/2025	136,948,872	Total net* of voting rights: 136,762,549

* Net total = total number of voting rights attached to shares – shares without voting rights

Stock Quote

Last Trade:	US$10.83
Daily Change:	-0.16 -1.46
Daily Volume:	2,574
Market Cap:	US$296.310M

June 25, 2025 DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old April 30, 2025 DBV Technologies Reports First Quarter 2025 Financial Results March 27, 2025 DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved March 24, 2025 DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results... January 08, 2025 DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study LOAD MORE NEWS

Featured Stock

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE